Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

The reactor building at the Bushehr nuclear power plant. Photo: IIPA via Getty Images

Iran's Deputy Foreign Minister Abbas Araghchi said on Sunday the country would break within hours the limit on uranium enrichment set in the 2015 nuclear deal, BBC reports.

Details: Araghchi said Iran would start enriching uranium above the 3.67% limit to provide fuel for its Bushehr power plant, according to BBC, which reported that officials said this would mean a concentration of about 5%.

"This is to protect the nuclear deal, not to nullify it. This is an opportunity for talks. And if our partners fail to use this opportunity they should not doubt our determination to leave the deal."
— Araghchi

Why it matters: Iran has already admitted breaching the deal. It said last week its stockpile of low-enriched uranium crossed 300 kilograms (661 pounds) — the maximum amount it's allowed to hold under the 2015 nuclear deal, which has been in jeopardy since the U.S. withdrew from it.

  • Iranian President Hassan Rouhani said last week that Tehran would start enriching uranium to "any amount we want" on July 7.

The big picture: Araghchi told a news conference Iran would scale back other commitments in 60 days if there's no progress in talks with European countries on the nuclear deal, according to Al Jazeera.

  • French President Emmanuel Macron said on Saturday that France and Iran had agreed to explore by July 15 conditions to resume talks on the nuclear deal, per Euronews.
  • The situation between Iran and the United States remains tense. Last month, Iran shot down a U.S. drone. Trump called off retaliatory airstrikes at the last minute.

Go deeper: How Trump and Tehran came to the brink of war

This article has been updated with more details, including fresh comment from Araghchi.

Go deeper

Caitlin Owens, author of Vitals
3 hours ago - Health

Pfizer CEO feels "liberated" after taking COVID vaccine

Pfizer CEO Albert Bourla. Photo: "Axios on HBO"

Pfizer CEO Albert Bourla tells "Axios on HBO" that he recently received his first of two doses of the company's coronavirus vaccine.

Why it matters: Bourla told CNBC in December that company polling found that one of the most effective ways to increase confidence in the vaccine was to have the CEO take it.

Dan Primack, author of Pro Rata
3 hours ago - Economy & Business

Ripple CEO: SEC lawsuit is "bad for crypto" in the U.S.

Ripple CEO Brad Garlinghouse tells "Axios on HBO" that if his company loses a lawsuit brought by U.S. regulators, it would put the country at a competitive disadvantage when it comes to cryptocurrencies.

Between the lines: The SEC in December sued Ripple, and Garlinghouse personally, for allegedly selling over $1.3 billion in unregistered securities. Ripple's response is that its cryptocurrency, called XRP, didn't require registration because it's an asset rather than a security.

Caitlin Owens, author of Vitals
3 hours ago - Health

Pfizer CEO: "It will be terrible" if COVID-19 vaccine prices limit access

Pfizer CEO Albert Bourla told "Axios on HBO" that it "will be terrible for society" if the price of coronavirus vaccines ever prohibits some people from taking them.

Why it matters: Widespread uptake of the vaccine — which might require annual booster shots — will reduce the risk of the virus continuing to spread and mutate, but it's unclear who will pay for future shots or how much they'll cost.